THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional advisor.

If you have sold or transferred all your shares in **EPS Creative Health Technology Group Limited**, you should at once hand this circular and the accompanying form of proxy to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3860)

(1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES;
(2) PROPOSED RE-ELECTION OF DIRECTORS;
(3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND
(4) PROPOSED FINAL DIVIDEND; AND
(5) NOTICE OF ANNUAL GENERAL MEETING

A notice convening the AGM (as defined herein) to be held at Hong Kong at 35/F, Dah Sing Financial Centre, 248 Queen's Road East, Wanchai, Hong Kong at 10:00 a.m. on Friday, 15 August 2025 is set out on pages 22 to 27 of this circular. A form of proxy for use at the AGM is enclosed with this circular.

Whether or not you are able to attend and vote at the AGM, you are requested to complete and sign the accompanying form of proxy in accordance with the instructions printed thereon and deposit the same at the office of Hong Kong branch share registrar and transfer office of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible and in any event not less than 48 hours (i.e 10:00 a.m. on Wednesday, 13 August 2025) before the time appointed for holding the AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish and, in such event, the instrument appointing the proxy shall be deemed to be revoked.

21 July 2025

CONTENTS

Page

Definitions 1

Expected Timetable 4

Letter from the Board

1. Introduction 5
2. Issuance Mandate 6
3. Repurchase Mandate 7
4. Re-election of Directors 7
5. Re-appointment of Auditors 9
6. Final Dividend 9
7. AGM and Proxy Arrangement. 9
8. Recommendation 10
9. Closure of Register of Members 10
10. General 10

Appendix I — Explanatory Statement on the Repurchase Mandate 11

Appendix II — Details of Directors Proposed to be Re-elected 15

Notice of Annual General Meeting 22

In this circular and the appendices to it, unless the context otherwise requires, the following expressions shall have the following meanings:

"AGM"	the annual general meeting of the Company to be convened and held at 35/F, Dah Sing Financial Centre, 248 Queen's Road East, Wanchai, Hong Kong at 10:00 a.m. on Friday, 15 August 2025 (or any adjourned meeting thereof) for the purpose of considering, if thought fit, approving the resolutions proposed in the AGM Notice;
"AGM Notice"	the notice convening the AGM set out on pages 22 to 27 of this circular;
"Articles of Association"	the articles of association of the Company as amended are restated from time to time;
"Audit Committee"	the audit committee of the Company;
"Auditors"	the auditors of the Company from time to time;
"Board"	the board of Directors;
"CCASS"	Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited, a securities settlement system used within the Hong Kong Exchanges and Clearing Limited market system
"close associate(s)"	has the meaning ascribed thereto under the Listing Rules;
"Company"	EPS Creative Health Technology Group Limited, a company incorporated in the Cayman Islands with limited liability and its Shares are listed on the Main Board of the Stock Exchange;
"controlling shareholder(s)"	has the meaning ascribed thereto under the Listing Rules;
"core connected person(s)"	has the meaning ascribed thereto under the Listing Rules;
"Director(s)"	the director(s) of the Company;
"Final Dividend"	the proposed final dividend of HK 1.0 cent per Share for the year ended 31 March 2025 to the Shareholders whose names appear on the register of members of the Company on the Record Date;
"Group"	the Company and its subsidiaries;
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China;

"Issuance Mandate"	a general and unconditional mandate to be granted to the Directors to allot and issue and deal with unissued Share of not exceeding 20% of the total number of issued Shares (excluding Treasury Shares, if any) as at the date of passing of the proposed ordinary resolution contained in item 5 of the AGM Notice as set out on pages 23 to 24 of this circular;
"Latest Practicable Date"	15 July 2025, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information in this circular;
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange;
"Nomination Committee"	the nomination committee of the Company;
"Remuneration Committee"	the remuneration committee of the Company;
"PRC"	the People's Republic of China, but for the purpose of this circular only and except where the context requires otherwise, references in this circular to "China" or "PRC" do not include Hong Kong, the Macau Special Administrative Region and Taiwan;
"Record Date"	Wednesday, 27 August 2025, being the record date for determining entitlement of the Shareholders to the Final Dividend;
"Repurchase Mandate"	a general and conditional mandate to be granted to the Directors to repurchase Shares on the Stock Exchange not exceeding 10% of the total number of issued Shares (excluding Treasury Shares, if any) as at the date of passing of the proposed ordinary resolution contained in item 6 of the AGM Notice as set out on pages 24 to 25 of this circular;
"SFO"	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong;
"Share(s)"	ordinary share(s) of nominal value of HK$0.01 each in the issued share capital of the Company;
"Shareholder(s)"	holder(s) of the Share(s);
"Stock Exchange"	The Stock Exchange of Hong Kong Limited;
"substantial shareholder(s)"	has the meaning ascribed thereto under the Listing Rules;
"Takeovers Code"	The Code on Takeovers and Mergers issued by the Securities and Futures Commission of Hong Kong as amended from time to time;

"Treasury Shares"	has the meaning ascribed thereto under the Listing Rules;
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong; and
"%"	per cent.

The expected timetable for the AGM and payment of the Final Dividend is as follows:

Event	Date
Latest date and time for the Shareholders to lodge transfer documents to the Company's branch share registrar and transfer office in Hong Kong in order to qualify for attending and voting at the AGM	4:30 p.m. on Monday, 11 August 2025
Closure of the register of members of the Company for determining the entitlement to attend and vote at the AGM	Tuesday, 12 August 2025 to Friday, 15 August 2025 (both days inclusive)
Latest date and time for returning of form of proxy to the Company's branch share registrar and transfer office in Hong Kong	10:00 a.m. on Wednesday, 13 August 2025
Record date for determining the entitlement to attend and vote at the AGM	Friday, 15 August 2025
Date and time of the AGM	10:00 a.m. on Friday, 15 August 2025
Final Dividend ex-entitlement date	Wednesday, 20 August 2025
Latest date and time for the Shareholders to lodge transfer documents to the Company's branch share registrar and transfer office in Hong Kong in order to qualify for receiving the Final Dividend	4:30 p.m. on Thursday, 21 August 2025
Closure of the register of members of the Company for determining the entitlement to the Final Dividend	Friday, 22 August 2025 to Wednesday, 27 August 2025 (both days inclusive)
Record Date for determining the entitlement to the Final Dividend	Wednesday, 27 August 2025
The expected payment date of the Final Dividend (subject to the Shareholders' approval of the declaration of the Final Dividend at the AGM)	Wednesday, 17 September 2025

EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3860)

Executive Directors:
Mr. Washikita Kenichiro *(Chairman and Chief Executive Officer)*
Mr. Miyano Tsumoru
Mr. Narumi Shoichi
Mr. Chiu Chun Tak
Ms. Du Yao
Mr. Liang Fei

Non-executive Directors
Mr. Uematsu Takahiro
Mr. Yan Ping

Independent non-executive Directors:
Mr. Chan Cheuk Ho
Mr. Choi Koon Ming
Mr. Saito Hironobu
Ms. Zhang Cuiping

Registered office:
Cricket Square, Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

Head office and principal place of business in Hong Kong:
Flat A, 17/F., Gemstar Tower
23 Man Lok Street
Hung Hom, Kowloon Hong Kong

21 July 2025

To the Shareholders,

Dear Sir or Madam,

(1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; (2) PROPOSED RE-ELECTION OF DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) PROPOSED FINAL DIVIDEND; AND (5) NOTICE OF ANNUAL GENERAL MEETING

1. INTRODUCTION

At the AGM to be held at 35/F, Dah Sing Financial Centre, 248 Queen's Road East, Wanchai, Hong Kong at 10:00 a.m. on Friday, 15 August 2025, resolutions will be proposed, among other matters:

(a) to grant the Issuance Mandate to the Directors;

(b) to grant the Repurchase Mandate to the Directors;

(c) to re-elect the Directors;

(d) to re-appoint Confucius International CPA Limited as the Auditors; and

(e) to declare and pay the Final Dividend.

The purpose of this circular is to provide the Shareholders with (a) the AGM Notice and (b) information relating to the resolutions to be proposed at the AGM for (i) the Issuance Mandate (including the extension of the Issuance Mandate); (ii) the Repurchase Mandate; (iii) the re-election of the Directors; (iv) the re-appointment of the Auditors; and (v) the declaration and payment of the Final Dividend.

2. ISSUANCE MANDATE

Ordinary resolutions will be proposed at the AGM in relation to the Issuance Mandate and authorisation of the extension of the Issuance Mandate to allot, issue and deal with (including the resale and transfer of Treasury Shares) the Shares repurchased by the Company under the Repurchase Mandate, details of which are set out in ordinary resolutions 5 and 7 of the AGM Notice. The Shares which may be allotted and issued pursuant to the Issuance Mandate are limited to a maximum of 20% of the aggregate number of Shares in issue (excluding Treasury Shares, if any) at the date of passing the proposed resolution of the Issuance Mandate at the AGM. On the basis that 522,177,419 Shares were in issue as at the Latest Practicable Date and no further Shares are issued or repurchased prior to the AGM, exercise in full of the Issuance Mandate (without being extended by the number of Shares (if any) repurchased by the Company under the Repurchase Mandate) could result in up to 104,435,483 Shares being allotted and issued by the Company.

The Issuance Mandate will remain in effect until the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable law of the Cayman Islands to be held; or (iii) the passing of an ordinary resolution by the Shareholders in general meeting of the Company revoking or varying the authority given to the Directors.

Subject to and conditional on the passing of the ordinary resolutions in relation to the Issuance Mandate and the Repurchase Mandate, an ordinary resolution will be proposed at the AGM to extend the Issuance Mandate by adding to the Issuance Mandate those Shares repurchased by the Company under the Repurchase Mandate provided that such extended amount shall not exceed 10% of the aggregate number of Shares in issue (excluding Treasury Shares, if any) on the date of passing of the resolution in relation to the Repurchase Mandate.

3. REPURCHASE MANDATE

An ordinary resolution will be proposed at the AGM in relation to the Repurchase Mandate, details of which are set out in ordinary resolution 6 of the AGM Notice. The Shares which may be repurchased pursuant to the Repurchase Mandate are limited to a maximum of 10% of the aggregate number of Shares in issue (excluding Treasury Shares, if any) at the date of passing of the proposed resolution of the Repurchase Mandate at the AGM.

The Repurchase Mandate will remain in effect until the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable law of the Cayman Islands to be held; or (iii) the passing of an ordinary resolution by the Shareholders in general meeting of the Company revoking or varying the authority given to the Directors.

In accordance with the requirements of the Listing Rules, the Company is required to send to the Shareholders an explanatory statement containing all the information reasonably necessary to enable them to make an informed decision on whether to vote for or against the granting of the Repurchase Mandate. The explanatory statement as required by the Listing Rules in connection with the Repurchase Mandate is set out in Appendix I to this circular.

The Directors currently have no immediate plan to exercise the Issuance Mandate or the Repurchase Mandate (if granted to the Directors at the AGM).

4. RE-ELECTION OF DIRECTORS

As at the Latest Practicable Date, the Board comprises Mr. Washikita Kenichiro, Mr. Miyano Tsumoru, Mr. Narumi Shoichi, Mr. Chiu Chun Tak, Ms. Du Yao and Mr. Liang Fei as executive Directors; Mr. Uematsu Takahiro and Mr. Yan Ping as non-executive Directors; Mr. Chan Cheuk Ho, Mr. Choi Koon Ming, Mr. Saito Hironobu and Ms. Zhang Cuiping as independent non-executive Directors.

Pursuant to Article 83(3) of the Articles of Association, the Board shall have the power from time to time and at any time to appoint any person as a Director either to fill a casual vacancy on the Board or as an addition to the existing Board. Any Director so appointed shall hold office only until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election. Accordingly, Mr. Washikita Kenichiro, Mr. Narumi Shoichi, Ms. Du Yao, Mr. Liang Fei, Mr. Uematsu Takahiro and Ms. Zhang Cuiping shall retire at the AGM and being eligible, will offer themselves for re-election at the AGM.

Pursuant to Article 84(1) of the Articles of Association, one-third of the Directors for the time being shall retire from office by rotation at every annual general meeting of the Company and every Director shall be subject to retirement by rotation at least once every three years. A retiring Director shall be eligible for re-election. Further, pursuant to Article 84(2) of the Articles of Association, any Director appointed by the Board pursuant to Article 83(3) shall not be taken into account in

determining which particular Directors or the number of Directors who are to retire by rotation. In accordance with Article 84, Mr. Chiu Chun Tak and Mr. Choi Koon Ming shall retire at the AGM and, being eligible, offer themselves for re-election at the AGM.

Nomination policy and process for independent non-executive Directors

In reviewing the structure of the Board, the Nomination Committee will consider the structure, size and diversity (including gender, age, cultural and educational background, length of service, skills, knowledge and experience etc.) of the Board at least annually and make recommendations on any proposed changes to the Board to complement the Company's corporate strategy. All appointments to the Board are based on meritocracy and the candidates will be assessed based on criteria such as education background and relevant skills and experience for consideration of the operation of the Board as a whole, with a view to maintaining a sound balance of the Board's composition. When making recommendations regarding the appointment of any proposed candidate(s) for directorships to the Board or re-appointment of any existing member(s) of the Board, the Nomination Committee shall consider a variety of factors including but not limited to accomplishment, experience, reputation in the healthcare industry and apparel industry and other relevant sectors, time commitment in terms of interest and attention to the Group's business and potential contributions bring to the Board, and the independence of the independent non-executive Directors.

For the independent non-executive Directors proposed to be re-elected at the AGM, Mr. Choi Koon Ming has years of experience in the financing activities of corporate and has been acting as the chief executive officer or non-executive director of various companies listed on the Stock Exchange; and Ms. Zhang Cuiping has qualification in Chinese Law and has over 20 years of experience in the legal and business practice of both the PRC and Japan, including investment and M&A between the PRC. During their terms as independent non-executive Directors, each of them has demonstrated that he/she has the required character, integrity and experience to perform his/her duties by providing objective views and independent guidance to the Board. Each of them has confirmed his/her independence with reference to the factors set out in Rule 3.13 of the Listing Rules. The Board is of the view that each of Mr. Choi Koon Ming and Ms. Zhang Cuiping has been committed to devoting time and attention to perform his/her duties as independent non-executive Director and that his/her wide breadth of professional experience and knowledge in his/her field have been and will continue to contribute greatly to the diversity of the Board, and they are independent in accordance with the independence guidelines set out in the Listing Rules. As such, the Board considers that the re-election of each of Mr. Choi Koon Ming and Ms. Zhang Cuiping as independent non-executive Director is in the best interest of the Company and the Shareholders as a whole.

Further, the Board considers that the re-election of each of Mr. Washikita Kenichiro, Mr. Narumi Shoichi, Mr. Chiu Chun Tak, Ms. Du Yao, Mr. Liang Fei and Mr. Uematsu Takahiro, as an executive Director or a non-executive Director (as the case may be) is in the best interest of the Company and the Shareholders as a whole. Each of the Directors should abstain from voting on the respective propositions of their recommendations for re-election by the Shareholders.

Particulars relating to the Directors proposed to be re-elected at the AGM are set out in Appendix II to this circular.

5. RE-APPOINTMENT OF AUDITORS

Confucius International CPA Limited ("**Confucius International**") will retire as the Auditors at the AGM and being eligible, offer themselves for re-appointment as the Auditors.

In accordance with Rule 13.88 of the Listing Rules, an ordinary resolution will be proposed at the AGM to re-appoint Confucius International as the Auditors to hold office from the conclusion of the AGM until the next annual general meeting and to authorise the Board to fix its remuneration for the year ended 31 March 2026.

6. FINAL DIVIDEND

As disclosed in the annual results announcement of the Company for the year ended 31 March 2025, the Board has resolved to recommend the payment of the Final Dividend of HK1.0 cent per Share for the year ended 31 March 2025 to the Shareholders whose names appear on the register of members of the Company on the Record Date. The declaration and payment of the Final Dividend is subject to the approval by the Shareholders at the AGM. Please refer to the section headed "Expected Timetable" for further details on closure of the register of members of the Company for entitlement to the Final Dividend.

7. AGM AND PROXY ARRANGEMENT

The AGM Notice convening the AGM to be held at 10:00 a.m. on Friday, 15 August 2025 at 35/F, Dah Sing Financial Centre, 248 Queen's Road East, Wanchai, Hong Kong is set out on pages 23 to 27 of this circular. At the AGM, resolutions will be proposed, inter alia, to approve (i) the grant of the Issuance Mandate (including the extension of the Issuance Mandate) and the Repurchase Mandates; (ii) the re-election of Directors; (iii) the re-appointment of the Auditors; and (iv) the declaration and payment of the Final Dividend.

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll. Therefore, all resolutions as set out in the AGM Notice to be proposed at the AGM shall be voted by poll. The Company will announce the results of the vote by poll in the manner prescribed under Rule 13.39(5) of the Listing Rules following the conclusion of the AGM.

A form of proxy for use at the AGM is enclosed with this circular and such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.epshk.hk). In order to be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with a power of attorney or other authority, if any, under which it is signed or a certified copy of such power or authority, at the Hong Kong branch share registrar and transfer office of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible and in any event not less than 48 hours (i.e 10:00 a.m. on Wednesday, 13 August 2025) before the time scheduled for holding the AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude any Shareholder from attending and voting in person at the AGM or any adjournment thereof should he/she/it so wishes. In that event, the form of proxy shall be deemed to be revoked.

Treasury Shares, if any and registered under the name of the Company, shall have no voting rights at the general meeting(s) of the Company. For the avoidance of doubt, for the purpose of the Listing Rules, Treasury Shares, if any, pending withdrawal from and/or transferring through CCASS shall not bear any voting rights at the Company's general meeting(s).

8. RECOMMENDATION

The Directors believe that the ordinary resolutions in relation to the Issuance Mandate (including the extension of the Issuance Mandate), the Repurchase Mandate, the re-election of the retiring Directors, the re-appointment of the Auditors and the payment of the Final Dividend are all in the interests of the Company and the Shareholders as a whole and therefore recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM as set out in the AGM Notice on pages 23 to 27 of this circular.

9. CLOSURE OF REGISTER OF MEMBERS

For the purpose of determining Shareholders' entitlements to attend and vote at the AGM, the transfer books and the register of members of the Company will be closed from Tuesday, 12 August 2025 to Friday, 15 August 2025 (both days inclusive), during which period no transfer of shares will be effected. In order to be eligible to attend and vote at the AGM, all transfers, accompanied by the relevant share certificates, must be lodged with the Company's Hong Kong branch share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Monday, 11 August 2025. The record date for the purpose of determining the Shareholders' entitlements to attend and vote at the AGM is Friday, 15 August 2025.

For determining the entitlement to the Final Dividend, the Register will be closed from Friday, 22 August 2025 to Wednesday, 27 August 2025, both days inclusive, during which period no transfer of Shares shall be effected. In order to be eligible to receive the Final Dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Share Registrar for registration no later than 4:30 p.m. on Thursday, 21 August 2025. The Final Dividend is expected to be paid on Wednesday, 17 September 2025. The record date for the purpose of determining the entitlement to the Final Dividend is Wednesday, 27 August 2025.

10. GENERAL

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder is required to abstain from voting on any resolutions to be proposed at the AGM.

Your attention is drawn to the additional information set out in the appendices to this circular.

Yours faithfully,
By order of the Board
EPS Creative Health Technology Group Limited
Washikita Kenichiro
Executive Director

This Appendix I serves as an explanatory statement, as required by the Listing Rules, to provide the requisite information to the Shareholders to enable them to make an informed decision on whether to vote for or against the ordinary resolution concerning the Repurchase Mandate proposed to be granted to the Directors at the AGM.

1. REPURCHASE OF SECURITIES FROM CORE CONNECTED PERSONS

The Listing Rules prohibit a company from knowingly repurchasing securities on the Stock Exchange from a "core connected person", that is, a director, chief executive or substantial shareholder of the Company or any of its subsidiaries or their respective close associate and a core connected person is prohibited from knowingly selling his/her/its securities to the Company.

No core connected person has notified the Company that he/she/it has a present intention to sell any Shares to the Company, or that any core connected person has undertaken not to sell any of the Shares held by him/her/it to the Company in the event that the Repurchase Mandate is approved by the Shareholders at the AGM.

2. REASONS FOR REPURCHASES

The Directors believe that it is in the best interests of the Company and the Shareholders as a whole to have a general authority from the Shareholders to enable the Directors to repurchase Shares on the market. When exercising the Repurchase Mandate, the Directors may, subject to market conditions and the Company's capital management needs at the relevant time of the repurchase, resolve to cancel the shares repurchased following settlement of any such repurchase or hold them as Treasury Shares. Shares repurchased for cancellation may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net assets value per Share and/or earnings per Share. On the other hand, Shares repurchased and held by the Company as Treasury Shares may be resold on the market at market prices to raise funds for the Company, or transferred or used for other purposes, subject to compliance with the Listing Rules, the Memorandum and Articles of Association, and the laws of the Cayman Islands. Repurchase of Shares will only be made when the Directors believe that such repurchases will benefit the Company and the Shareholders as a whole.

The Directors are seeking the granting of the Repurchase Mandate to give the Company the flexibility to do so if and when appropriate. The number of Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time, having regard to the circumstances then pertaining.

The Directors have no present intention to cause the Company to repurchase any Shares and they would only exercise the power to do so under circumstances where they consider that doing so would be in the best interests of the Company and the Shareholders as a whole.

3. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 522,177,419 Shares.

Subject to the passing of the ordinary resolution for the approval of the Repurchase Mandate and on the basis that no further Shares are issued or repurchased after the Latest Practicable Date and up to the date of the AGM, the Directors would be authorised to repurchase, during the period in which the Repurchase Mandate remains in force, a maximum of 52,217,741 Shares, representing 10% of the issued Shares (excluding Treasury Shares, if any) as at the date of passing of the proposed resolution of the Repurchase Mandate at the AGM, and which will remain in effect until the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association, or any applicable law of the Cayman Islands to be held; or (iii) the revocation or variation of the Repurchase Mandate by an ordinary resolution of the Shareholders in a general meeting of the Company prior to its next annual general meeting.

4. FUNDING OF REPURCHASES

Pursuant to the Repurchase Mandate, repurchases would be funded entirely from the Company's available cash flow or working capital facilities which will be funds legally available under the applicable laws of the Cayman Islands, the Memorandum and Articles of Association, the Listing Rules for such purpose and/or any other applicable laws as the case may be.

5. IMPACT OF REPURCHASES ON WORKING CAPITAL OR GEARING LEVEL

As compared with the financial position of the Company as at 31 March 2025 (being the date to which the latest audited accounts of the Company have been made up), the Directors consider that there might be a material adverse impact on the working capital and on the gearing position of the Company in the event that the proposed repurchases were to be carried out in full during the proposed repurchase period.

The Directors do not intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital or gearing position of the Company.

For Treasury Shares deposited with CCASS pending resale on the Stock Exchange, the Company will adopt appropriate measures to ensure that it would not exercise any Shareholders' rights or receive any entitlements which would otherwise be suspended under the relevant laws if those shares were registered in the Company's own name as Treasury Shares, which may include approval by the Board that (i) the Company will not (or will procure its broker not to) give any instructions to Hong Kong Securities Clearing Company Limited to vote at general meetings for the Treasury Shares deposited with CCASS; and (ii) in the case of dividends or distributions, the Company will withdraw the Treasury Shares from CCASS, and either re-register them in its own name as Treasury Shares or cancel them, in each case before the record date for the dividends or distributions.

Shareholders and potential investors of the Company are advised to pay attention to any announcement to be published by the Company in the future, including but without limitation, any relevant next day disclosure return (which shall identify, amongst others, the number of repurchased

shares that are to be held in treasury or cancelled upon settlement of such repurchase, and where applicable, the reasons for any deviation from the intention statement previous disclosed) and any relevant monthly return.

6. SHARES PRICES

The highest and lowest prices of the Shares recorded on the Stock Exchange in each of the last twelve months immediately preceding and including the Latest Practicable Date were as follows:

	Share Price (Per Share)	
	Highest	**Lowest**
Month	*HK$*	*HK$*
July 2024	0.910	0.700
August 2024	0.730	0.610
September 2024	0.750	0.620
October 2024	0.720	0.470
November 2024	0.660	0.450
December 2024	0.660	0.470
January 2025	0.540	0.475
February 2025	0.530	0.460
March 2025	0.520	0.475
April 2025	0.520	0.410
May 2025	0.520	0.490
June 2025	0.570	0.480
July 2025 (up to the Latest Practicable Date)	0.510	0.440

7. DIRECTORS, THEIR CLOSE ASSOCIATES AND CONNECTED PERSONS

None of the Directors nor, to the best of their knowledge and belief having made all reasonable enquiries, any of their respective close associates, have any present intention to sell to the Company or its subsidiaries any of the Shares in the event that the Repurchase Mandate is approved by the Shareholders at the AGM.

8. UNDERTAKING OF THE DIRECTORS

The Directors will exercise the powers of the Company to make repurchases pursuant to the Repurchase Mandate in accordance with the Listing Rules and applicable laws of the Cayman Islands, the Memorandum and Articles of Association.

The Company confirms that the explanatory statement set out in this Appendix contains the information required under Rule 10.06(1)(b) of the Listing Rules and that neither the explanatory statement set out in this Appendix nor the Repurchase Mandate has unusual features.

9. EFFECT OF THE TAKEOVERS CODE

If as a result of a repurchase of Shares under the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of Rule 32 of the Takeovers Code. As a result, a Shareholder or a group of Shareholders acting in concert (as defined in the Takeovers Code), depending on the level of increase of the shareholding, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code for all the Shares not already owned by such Shareholder or group of Shareholders.

As at the Latest Practicable Date, the only controlling shareholder is EPS Holdings, Inc. ("**EPS Japan**"), a company incorporated in Japan with limited liability, which owned 375,000,000 Shares (representing 71.8% of the issued share capital of the Company) as at the Latest Practicable Date. In the event that the Repurchase Mandate was exercised in full, the interest of EPS Japan would be increased from 71.8% to approximately 79.8%. On the basis of the aforesaid increase of shareholding held by EPS Japan, the Directors are not aware of any consequences of such repurchases of Shares that would result in a Shareholder, or group of Shareholders acting in concert, becoming obliged to make a mandatory offer under Rule 26 of the Takeovers Code if the Repurchase Mandate was exercised in full. Moreover, the Directors do not intend to exercise the power to repurchase Shares to an extent which would render any Shareholder or group of Shareholders obliged to make a mandatory offer under Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, the Directors had no intention to exercise the Repurchase Mandate to such extent as to result in the number of the issued Shares in the hands of public falling below the minimum prescribed percentage of 25% as required by the Listing Rules.

10. LISTING RULES RELATING TO REPURCHASE OF SHARES

The Listing Rules permit companies with a primary listing on the Stock Exchange to repurchase their shares on the Stock Exchange and any other stock exchange on which the securities of the company are listed and recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange subject to certain restrictions.

The Listing Rules provide that all proposed repurchases of shares must be approved by shareholders in advance by an ordinary resolution at a general meeting, either by way of a general repurchase mandate or by a specific approval of a particular transaction and that the shares to be repurchased must be fully paid up.

11. SHARES REPURCHASE MADE BY THE COMPANY

No repurchases of Shares have been made by the Company or any of its subsidiaries (whether on the Stock Exchange or otherwise) during the last six months immediately preceding the Latest Practicable Date.

The biographical details of the Directors proposed to be re-elected at the AGM are set out as follows:

(1) Mr. Washikita Kenichiro (鷲北健一郎) ("Mr. Washikita")

Mr. Washikita, aged 61, was appointed as an executive Director, the chairman and the chief executive officer of the Company with effect from 8 November 2024. He is the corporate officer of EPS Holdings, Inc. ("**EPS Japan**"), which is a controlling shareholder (as defined under the Listing Rules) of the Company. Mr. Washikita joined EPS Japan in April 2024 and has over 37 years of experience in diversified business areas including apparel and medical healthcare. Prior to joining EPS Japan, Mr. Washikita worked in Mitsui & Co., Ltd., a Japanese company which is part of the Mitsui Group, an international group offering diversified services worldwide, from 1987 to March 2024 in which he had been the General Manager of various business units and the Chairman and Managing Director of Mitsui & Co. (Hong Kong) Ltd. He also served in various positions within the Hong Kong Japanese Chamber of Commerce and Industry, being the President from April to June 2018, the Vice President from July 2018 to June 2019 and from July 2022 to March 2024, and the first Health Care & Medical Committee Head from September 2021 to March 2024. Mr. Washikita is a colleague of Mr. Miyano Tsumoru, Mr. Chiu Chun Tak, Mr. Narumi Shoichi and Mr. Uematsu Takahiro in EPS Japan.

Mr. Washikita graduated from Waseda University in Shinjuku, Tokyo, Japan, majoring in B.A. Political Science and Economic in 1987. He also received an MBA degree from Aoyama Gakuin University in Shibuya, Tokyo, Japan in 2007.

Mr. Washikita has entered into an appointment letter with the Company for an initial term of two years commencing from 8 November 2024 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association. Mr. Washikita is currently entitled to a director's remuneration of JPY353,000 per month on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2025, Mr. Washikita has received emoluments in the aggregate sum of HK$88,000 (including salary and other benefits).

As at the Latest Practicable Date, save as disclosed above, Mr. Washikita (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Mr. Washikita that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(2) Mr. Narumi Shoichi (鳴海尚一) ("Mr. Narumi")

Mr. Narumi, aged 43, was appointed as an executive Director and the chief financial officer of the Company with effect from 2 December 2024. He is the deputy director of the business development office of EPS Holdings, Inc. ("**EPS Japan**"), which is a controlling shareholder (as defined under the Listing Rules) of the Company. Mr. Narumi joined the EPS Japan Group in 2007 and has over 15 years of experience in pharmaceutical development and cross-border business and possesses expertise in finance, taxation, strategic planning, and corporate governance. Currently, Mr. Narumi is serving as an executive officer and director in multiple global companies. Mr. Narumi is a colleague of Mr. Washikita, Mr. Miyano Tsumoru and Mr. Chiu Chun Tak and Mr. Uematsu Takahiro in EPS Japan.

Mr. Narumi graduated from Saitama University in Saitama, Japan, majoring in Molecular Biology. He also received a Master of Science from Saitama University.

Mr. Narumi has entered into an appointment letter with the Company for an initial term of two years commencing from 2 December 2024 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association. Mr. Narumi is currently entitled to a director's remuneration of JPY190,000 per month on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2025, Mr. Narumi has received emoluments in the aggregate sum of HK$39,000 (including salary and other benefits).

As at the Latest Practicable Date, save as disclosed above, Mr. Narumi (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Mr. Narumi that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(3) Mr. Chiu Chun Tak (趙俊德) ("Mr. Chiu")

Mr. Chiu, aged 61, was appointed as an executive Director with effect from 1 November 2023 and has been appointed as the Company Secretary, an authorised representative of the Company under the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), all with effect from 30 June 2021. Mr. Chiu graduated from the Hong Kong Polytechnic University majoring in accounting. He has over 32 years of experience in overseeing accounting, auditing, corporate finance, merger and acquisition, taxation and company secretarial business. He is a Hong Kong practicing CPA and a fellow member of Hong Kong Institute of Certified Public Accountants. Prior to joining the Group, Mr. Chiu was the founder of C.T. Chiu & Co., CPA and has also worked in a multinational company. Mr. Chiu has been appointed as the Senior Manager in Charge of

Business Planning & Promotion Division Emerging Business Centre Finance & Accounting Office of EPS Holdings, Inc., which is a controlling shareholder (as defined under the Listing Rules) of the Company, since 1 April 2024. He has since become a colleague of Mr. Washikita, Mr. Miyano Tsumoru, Mr. Narumi and Mr. Uematsu Takahiro in EPS Japan.

Mr. Chiu has entered into an appointment letter with the Company for an initial term of two years commencing from 1 November 2023 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association. Mr. Chiu is currently entitled to a director's remuneration of HK$57,000 per month on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2025, Mr. Chiu has received emoluments in the aggregate sum of HK$1,268,000 (including salary and other benefits, retirement benefits scheme contribution and equity-settled share-based expenses).

As at the Latest Practicable Date, Mr. Chiu is interested in 5,000,000 underlying Shares, representing the underlying Shares which may be issued in respect of options granted to him under the share option scheme of the Company, within the meaning of Part XV of the SFO.

As at the Latest Practicable Date, save as disclosed above, Mr. Chiu (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Mr. Chiu that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(4) Ms. Du Yao (杜垚) ("Ms. Du")

Ms. Du, aged 42, was appointed as an executive Director and the chief technology officer of the Company with effect from 2 December 2024. She is a member of the nomination committee of the Company. She started her career in Nihon L'Oreal and has over 13 years of experience in research and development in the skincare industry. Ms. Du founded Merry Plus Corporation in 2020 and BioBeaute Co., Ltd in 2024 and she has been acting as the chief executive officer of these companies.

Ms. Du graduated from Tokyo University majoring in Applied Life Science and Agriculture in 2007. She also received the Master of Pharmaceutical Science and PH. D of Pharmaceutical Science from Tokyo University in 2009 and 2012 respectively.

Ms. Du has entered into an appointment letter with the Company for an initial term of two years commencing from 2 December 2024 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association.

Ms. Du is currently entitled to a director's remuneration of JPY190,000 per month on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2025, Ms. Du has received emoluments in the aggregate sum of HK$39,000 (including salary and other benefits).

As at the Latest Practicable Date, save as disclosed above, Ms. Du (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Ms. Du that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(5) Mr. Liang Fei (梁非) ("Mr. Liang")

Mr. Liang, aged 50, was appointed as an executive Director with effect from 2 December 2024. He started working in EPS Japan since 2004 and is the chairman and the general manager of a non-wholly owned subsidiary of EPS Japan. Mr. Liang obtained a bachelor's degree from Southeast University majoring in information science and engineering in the People's Republic of China (the "**PRC**"), a master's degree in information engineering from Chiba University in Japan and an executive Master of Business Administration degree from China Europe International Business School. Before joining EPS Japan, Mr. Liang worked for several Japanese technology companies.

Mr. Liang has entered into an appointment letter with the Company for an initial term of two years commencing from 2 December 2024 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association. Mr. Liang is currently entitled to a director's remuneration of HK$10,000 per month on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2025, Mr. Liang has received emoluments in the aggregate sum of HK$40,000 (including salary and other benefits).

As at the Latest Practicable Date, save as disclosed above, Mr. Liang (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Mr. Liang that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(6) Mr. Uematsu Takahiro (植松高宏) ("Mr. Uematsu")

Mr. Uematsu, aged 59, was appointed as a non-executive Director with effect from 2 December 2024. He is a member of the audit committee of the Company. He is the head of compliance group of EPS Japan. He joined EPS Japan in January 2002 and has over 35 years of experience in product management and investment strategy management for research supply. Mr. Uematsu is a colleague of Mr. Washikita, Mr. Miyano Tsumoru, Mr. Chiu and Mr. Narumi in EPS Japan.

Mr. Uematsu graduated from Tokyo University of Agriculture and Technology.

Mr. Uematsu has entered into an appointment letter with the Company for an initial term of two years commencing from 2 December 2024 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association. Mr. Uematsu is currently entitled to a director's remuneration of JPY85,000 per month on a 12-month basis, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2025, Mr. Uematsu has received emoluments in the aggregate sum of HK$17,000 (including salary and other benefits).

As at the Latest Practicable Date, save as disclosed above, Mr. Uematsu (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Mr. Liang that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(7) Mr. Choi Koon Ming (蔡冠明) ("Mr. Choi")

Mr. Choi, aged 57, was appointed as an independent non-executive Director with effect from 30 June 2021and is responsible for providing independent judgment on the Group's strategy, performance, resources and standard of conduct. He is the chairman of both the remuneration committee and the nomination committee and a member of the audit committee of the Company. Mr. Choi holds a Bachelor of Arts degree from the University of British Columbia and has over 29 years of experience in the financing activities of corporate and property mortgage, real estate development and property investment.

Mr. Choi has been the chief executive officer of Sunwah Kingsway Capital Holdings Limited ("**Sunwah Kingsway**", stock code: 188.HK) since 2010 and an executive director of Sunwah Kingsway since 2000. Mr. Choi has also been the non-executive director of China New Economy Fund Limited (stock code: 80.HK) since February 2022.

Mr. Choi has entered into an appointment letter with the Company for an initial term of two years commencing from 30 June 2023 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association. Mr. Choi is currently entitled to a director's remuneration of HK$10,000 per month on a 12-month basis, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2024, Mr. Choi has received emoluments in the aggregate sum of HK$120,000 (including salary and other benefits).

As at the Latest Practicable Date, save as disclosed above, Mr. Choi (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Mr. Choi that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

(8) Ms. Zhang Cuiping (張翠萍) ("Ms. Zhang")

Ms. Zhang, aged 47, was appointed as an independent non-executive Director with effect from 2 December 2024. She is the partner of Nishimura & Asahi (Gaikokuho Kyodo Jigyo) and has over 20 years of experience in the legal and business practice of both the PRC and Japan, including investment and M&A between the PRC and Japan, corporate governance and data protection.

Ms. Zhang graduated from Beijing International Studies University and completed the LL.M. in Chinese Law from Renmin University of China Law School.

Ms. Zhang has entered into an appointment letter with the Company for an initial term of two years commencing from 2 December 2024 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Articles of Association. Ms. Du is currently entitled to a director's remuneration of JPY190,000 per month on a 12-month basis, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company. For the year ended 31 March 2025, Ms. Zhang has received emoluments in the aggregate sum of HK$38,000 (including salary and other benefits).

As at the Latest Practicable Date, save as disclosed above, Ms. Zhang (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there are no other matters relating to the re-election of Ms. Zhang that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3860)

BY GIVEN that the annual general meeting (the "**AGM**" and the "**Meeting**") of the shareholders (the "**Shareholders**") of EPS Creative Health Technology Group Limited (the "**Company**") will be held at 10:00 a.m. on Friday, 15 August 2025 at 35/F, Dah Sing Financial Centre, 248 Queen's Road East, Wanchai, Hong Kong for the purpose of considering the following ordinary business:

ORDINARY RESOLUTIONS

1. To consider and adopt the audited consolidated financial statements of the Company and the respective reports of the directors (the "**Directors**") of the Company and independent auditor of the Company for the year ended 31 March 2025.

2. To declare a final dividend of HK1.0 cent per ordinary share of HK$0.01 each in the share capital of the Company (the "**Share**") for the year ended 31 March 2025;

3. To re-appoint Confucius International CPA Limited as the independent auditor of the Company and to authorise the board (the "**Board**") of Directors of the Company to fix its remuneration.

4. (a) To re-elect Mr. Washikita Kenichiro as an executive Director.

   (b) To re-elect Mr. Narumi Shoichi as an executive Director.

   (c) To re-elect Mr. Chiu Chun Tak as an executive Director.

   (d) To re-elect Ms. Du Yao as an executive Director.

   (e) To re-elect Mr. Liang Fei as an executive Director.

   (f) To re-elect Mr. Uematsu Takahiro as a non-executive Director.

   (g) To re-elect Mr. Choi Koon Ming as an independent non-executive Director.

   (h) To re-elect Ms. Zhang Cuiping as an independent non-executive Director.

   (i) To authorise the Board to fix the respective Directors' remuneration.

5. To consider and, if thought fit, pass the following resolutions with or without amendments as an ordinary resolution:

"**THAT**:

(a) subject to paragraph (c) below, pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to allot, issue and deal with unissued Shares in the share capital of the Company, to sell and/or transfer Shares that are held as Treasury Shares (as defined in the Listing Rules) out of treasury, and to make or grant offers, agreements and options, including warrants, bonds and securities convertible into or exchangeable for the Shares, which might require the exercise of such powers be and the same is hereby generally and unconditionally approved;

(b) the approval in paragraph (a) above shall authorise the Directors during the Relevant Period to make or grant offers, agreements and options, including warrants, bonds and securities convertible into or exchangeable for the Shares, which would or might require the exercise of such powers after the end of the Relevant Period;

(c) the aggregate number of Shares allotted or agreed conditionally or unconditionally to be allotted and issued and Treasury Shares sold and/or transferred or agreed conditionally or unconditionally to be sold and/or transferred (whether pursuant to options or otherwise) by the Directors pursuant to the approval in paragraph (a) and (b) of this resolution above, otherwise than pursuant to:

(i) a Rights Issue (as defined below); or

(ii) an issue of Shares upon the exercise of any options granted under the share option scheme of the Company; or

(iii) an issue of Shares as scrip dividend or similar arrangements providing for the allotment and issue of Shares (including the sale and/or transfer of any Shares that are held as Treasury Shares out of treasury) in lieu of the whole or part of a dividend on Shares in accordance with the articles of association of the Company (the "**Articles of Association**") in force from time to time; or

(iv) an issue of Shares upon the exercise of rights of subscription or conversion or exchange under the terms of any warrants of the Company or any securities which are convertible into or exchangeable for the Shares,

shall not exceed the aggregate of 20% of the aggregate number of Shares in issue (excluding Treasury Shares, if any) as at the date of the passing of this Resolution and the authority pursuant to paragraph (a) of this Resolution shall be limited accordingly; and

(d) for the purposes of this Resolution,

"**Relevant Period**" means the period from the date of the passing of this Resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any other applicable laws of the Cayman Islands to be held; or

(iii) the passing of an ordinary resolution by the Shareholders in general meeting revoking or varying the authority given to the Directors by this Resolution.

"**Rights Issue**" means an offer of Shares, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to holders of Shares whose names appear on the register of members of the Company on a fixed record date in proportion to their then holdings of Shares (subject to such exclusion or other arrangements as the Directors may deem necessary or expedient in relation to overseas holders of the Shares or fractional entitlements, or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction outside Hong Kong or any recognised regulatory body or any stock exchange outside Hong Kong)."

6. To consider and, if thought fit, pass the following resolutions with or without amendments as an ordinary resolution:

"**THAT**:

(a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as defined below) of all powers of the Company to repurchase the shares in the share capital of the Company on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") or any other stock exchange on which the Shares may be listed and recognised by the Securities and Futures Commission of Hong Kong (the "**SFC**") and the Stock Exchange under the Hong Kong Code on Share Buy-backs issued by the SFC for such purpose, and otherwise in accordance with the rules and regulations of the SFC, the Stock Exchange, the Companies Act, Cap. 22 (Act 3 of 1961, as consolidated or revised) of the Cayman Islands and other applicable laws of the Cayman Islands and all other applicable laws in this regard, be and the same is hereby generally and unconditionally approved;

(b) the approval in paragraph (a) of this resolution above shall be in addition to any other authorisation given to the Directors and shall authorise the Directors on behalf of the Company during the Relevant Period to procure the Company to repurchase its Shares at a price determined by the Directors;

(c) the aggregate number of Shares which may be repurchased by the Company pursuant to the approval in paragraph (a) above of this Resolution during the Relevant Period shall not exceed 10% of the aggregate number of Shares in issue (excluding Treasury Shares, if any) as at the date of the passing of this Resolution and the authority pursuant to paragraph (a) of this Resolution shall be limited accordingly; and

(d) for the purposes of this Resolution,

"**Relevant Period**" means the period from the date of the passing of this Resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any other applicable laws of the Cayman Islands to be held; or

(iii) the passing of an ordinary resolution by the Shareholders in general meeting revoking or varying the authority given to the Directors by this Resolution."

7. To consider and, if thought fit, pass the following resolutions with or without amendments as an ordinary resolution:

"**THAT** conditional upon the passing of the ordinary resolutions 5 and 6 above as set out in this notice convening the Meeting, the general mandate granted to the Directors pursuant to ordinary resolution 5 as set out in this notice be and is hereby extended by the addition thereto the aggregate number of Shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued and any Shares that are held as Treasury Shares that may be sold and/or transferred out of treasury or agreed conditionally or unconditionally to be sold and/or transferred out of treasury by the Directors pursuant to or in accordance with such general mandate of an amount representing the aggregate number of Shares repurchased by the Company pursuant to or in accordance with the authority granted pursuant to ordinary resolution 6 as set out in this notice, provided that such amount shall not exceed 10% of the aggregate number of Shares in issue (excluding Treasury Shares, if any) as at the date of passing this resolution."

Yours faithfully,
By order of the Board
EPS Creative Health Technology Group Limited
Washikita Kenichiro
Executive Director

Hong Kong, 21 July 2025

As at the date of this notice, the executive Directors are Mr. Washikita Kenichiro, Mr. Miyano Tsumoru, Mr. Narumi Shoichi, Mr. Chiu Chun Tak, Ms. Du Yao and Mr. Liang Fei; the non-executive Directors are Mr. Uematsu Takahiro and Mr. Yan Ping; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Choi Koon Ming, Mr. Saito Hironobu and Ms. Zhang Cuiping.

Notes:

1. Any Shareholders entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and subject to the provisions of the Articles of Association, to vote on his/her/its behalf. A proxy need not be a Shareholder but must be present in person at the AGM to represent the Shareholder. If more than one proxy is so appointed, the appointment shall specify the number and class of Shares in respect of which each such proxy is so appointed. On a poll, votes may be given either personally or by proxy.

2. Whether or not Shareholders intend to attend the AGM in person, they are requested to complete, sign and return the accompanying form of proxy in accordance with the instructions printed thereon. Completion and return of a form of proxy will not preclude a Shareholder from attending and voting in person at the AGM or any adjournment thereof, should he/she/it so wishes.

3. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours (i.e 10:00 a.m. on Wednesday, 13 August 2025) before the time appointed for holding the AGM or any adjournment thereof.

4. In the case of joint holders of Shares, any one of such joint holders may vote at the AGM, either personally or by proxy, in respect of such Shares as if he/she/it was solely entitled thereto, but if more than one of such joint holders be present at the AGM personally or by proxy, that one of the said persons so present whose name stands first on the register of members in respect of such Shares shall alone be entitled to vote in respect thereof.

5. For determining Shareholders' entitlement to attend and vote at the AGM, the transfer books and the register of members of the Company will be closed from Tuesday, 12 August 2025 to Friday, 15 August 2025 (both days inclusive), during which period no transfer of Shares will be effected. In order to be eligible to attend and vote at the AGM, all transfer of Shares, accompanied by the relevant share certificates, must be lodged with the Company's Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Monday, 11 August 2025. The record date for the purpose of determining the Shareholders' entitlements to attend and vote at the AGM is Friday, 15 August 2025.

6. For determining the entitlement to the proposed final dividend, the register of members of the Company will be closed from Friday, 22 August 2025 to Wednesday, 27 August 2025, both days inclusive, during which period no transfer of Shares shall be effected. In order to be eligible to receive the proposed final dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Share Registrar for registration no later than 4:30 p.m. on Thursday, 21 August 2025. The proposed final dividend is expected to be paid on Wednesday, 17 September 2025. The record date for the purpose of determining the entitlement to the proposed final dividend is Wednesday, 27 August 2025.

7. (a) Subject to paragraph (b) below, if a tropical cyclone warning signal No. 8 or above or "extreme conditions" caused by super typhoons is expected to be hoisted or a black rainstorm warning signal is expected to be in force at any time after 7:00 a.m. on the date of the AGM, the AGM will be postponed and Shareholders will be informed of the date, time and venue of the postponed AGM by an announcement posted on the respective websites of the Company and the Stock Exchange.

(b) If a tropical cyclone warning signal No. 8 or above or "extreme conditions" caused by super typhoons or a black rainstorm warning signal is lowered or cancelled 3 hours before the time appointed for holding the AGM and where conditions permit, the AGM will be held as scheduled.

(c) The AGM will be held as scheduled when an amber or red rainstorm warning signal is in force. After considering their own situations, Shareholders should decide on their own whether or not they would attend the AGM under any bad weather condition and if they do so, they are advised to exercise care and caution.